Original Article
Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection
N Engl J Med 2005; 352:558-569February 10, 2005
- Abstract
Background
Antibodies against HLA antigens cause refractory allograft rejection with vasculopathy in some, but not all, patients.
Methods
We studied 33 kidney-transplant recipients who had refractory vascular rejection. Thirteen had donor-specific anti-HLA antibodies, whereas 20 did not. Malignant hypertension was present in 16 of the patients without anti-HLA antibodies, 4 of whom had seizures. The remaining 17 patients had no malignant hypertension. We hypothesized that activating antibodies targeting the angiotensin II type 1 (AT1) receptor might be involved.
Results
Activating IgG antibodies targeting the AT1 receptor were detected in serum from all 16 patients with malignant hypertension and without anti-HLA antibodies, but in no other patients. These receptor-activating antibodies are subclass IgG1 and IgG3 antibodies that bind to two different epitopes on the second extracellular loop of the AT1 receptor. Tissue factor expression was increased in renal-biopsy specimens from patients with these antibodies. In vitro stimulation of vascular cells with an AT1-receptor–activating antibody induced phosphorylation of ERK 1/2 kinase and increased the DNA binding activity of the transcription factors activator protein 1 (AP-1) and nuclear factor-κB. The AT1 antagonist losartan blocked agonistic AT1-receptor antibody–mediated effects, and passive antibody transfer induced vasculopathy and hypertension in a rat kidney-transplantation model.
Conclusions
A non-HLA, AT1-receptor–mediated pathway may contribute to refractory vascular rejection, and affected patients might benefit from removal of AT1-receptor antibodies or from pharmacologic blockade of AT1 receptors.
Media in This Article
Figure 1
Features of Refractory Rejection in Patients without Donor-Specific Anti-HLA Antibodies.Figure 2
Antibody Detection and Agonistic Activity as Indicated by a Bioassay Based on the Chronotropic Response of Neonatal-Rat Cardiomyocytes, Measured by the Increase in Beats per Minute.Article Activity
- Article
Many aspects of T-cell–mediated responses in allograft rejection have been elucidated, yet humoral mechanisms are relatively unexplored. Vascular rejection that is refractory to intensified immunosuppression is the most important predictor of early and late graft loss.1 The association of antidonor humoral reactivity against HLA antigens and vascular rejection has been established.2 Other targets of the allograft-directed host response remain elusive. However, alloantibodies against the polymorphic non-HLA system were found in serum obtained before transplantation from patients in whom refractory rejection developed after they received kidney transplants from HLA-identical siblings.3 Allograft endothelium may be a primary target of the cytopathic actions of non-HLA antibodies, triggering endothelial-cell activation or apoptosis.4,5 Identification of non-HLA antigens that are relevant to rejection might provide insight into underlying mechanisms, define risk-related phenotypes, and facilitate the development of specific therapies.
We studied kidney-transplant recipients who had severe allograft dysfunction but did not have anti-HLA antibodies; in these patients, rejection was invariably accompanied by accelerated hypertension, and even convulsions, in a manner reminiscent of preeclampsia. In fact, the first patient we examined in this group (the index patient) had had preeclampsia 16 years earlier. Immunologic similarities between graft rejection and fetal survival in pregnancies complicated by preeclampsia are well recognized.6 We previously reported that agonistic antibodies that target the angiotensin II type 1 (AT1) receptor may develop in women with preeclampsia after the 20th week of gestation,7 and we observed agonistic AT1-receptor activity in nine kidney-transplant recipients during an episode of rejection.8 We then reasoned that similar mechanisms might be present in refractory allograft rejection and initiated a comprehensive investigation of this issue.
Methods
Study Patients and Biopsies
We studied all patients with steroid-refractory acute renal-allograft rejection seen among those who received kidney transplants at the Charité University Hospital Campus Mitte in Berlin from January 1, 2000, through July 31, 2004. Serum samples were obtained prospectively from all patients during rejection episodes and were screened for donor-specific anti-HLA antibodies and also analyzed for agonistic antibodies targeting the AT1 receptor. Serum samples from patients with steroid-refractory acute vascular rejection from three collaborating centers (the Charité University Hospital Campus Virchow Clinic, and the University Hospital Erlangen–Nürnberg, both in Germany, and the Ospedale Civile in Bergamo, Italy) were also examined. Written informed consent to use serum samples for research purposes was obtained from each patient while he or she was awaiting transplantation. The institutional review board of Charité University Hospital Berlin approved the protocols.
Allograft-biopsy specimens were processed by standard techniques and graded according to the Banff 97 classification, with updated scoring of the degree of humoral rejection.9,10 Biopsy specimens were stained with polyclonal antibodies for C4d (Biomedica)11,12 and tissue factor (provided by T. Luther, Dresden).
Initial immunosuppressive therapy consisted of a calcineurin inhibitor, mycophenolate mofetil, methylprednisolone, and antibody against interleukin-2 receptor for induction. Patients who were positive for donor-specific anti-HLA antibodies or C4d or who had vascular rejection manifested as endarteritis or necrotizing vasculitis with fibrinoid necrosis were treated with plasmapheresis together with intravenous immune globulin. Patients initially treated with cyclosporine were switched to high-dose tacrolimus when refractory rejection was detected.
Bioassays and Analysis of Epitopes
Patients' serum samples were examined for the presence of AT1-receptor–activating IgG in a functional bioassay that involves spontaneously beating cultured neonatal-rat cardiomyocytes that express several G-protein–coupled receptors, including the AT1 receptor. Changes in the activation state of the cells is measured directly by counting the beating rate by means of computerized image analysis. Isolation, cultivation, and detection procedures have been described in detail previously.13 The dose–response relationship between activating IgG or angiotensin II concentration and the spontaneous beating rate is linear.
To study the specificity of the AT1 receptor–mediated response, IgG-stimulated cells were treated with an AT1-receptor blocker or angiotensin II type 2 (AT2)–receptor blocker. Short, overlapping synthetic peptides corresponding to the sequence of the second extracellular loop of the AT1 receptor were used for identification of epitopes. To identify the IgG subclass, IgG from 10 patients from whom sufficient serum was available were treated with murine monoclonal antihuman IgG1, IgG2, IgG3, and IgG4 antibodies.
Surface-Plasmon-Resonance Analysis
Binding of AT1-receptor antibody was verified and quantified by surface-plasmon-resonance analysis (BIAcore). The IgG fraction from affected patients or control human IgG was allowed to pass over biotinylated peptides loaded on a streptavidin-immobilized chip in a biosensor (BIAcore) at different flow rates. After the association phase and the dissociation phase, the relative increase in response of AT1-receptor peptide and control peptide (β2-adrenergic receptor) flow channels was determined. The kinetic variables were calculated with BIA evaluation software (Biosensor, version 3.1).
Assays
Human coronary-artery endothelial cells and vascular smooth-muscle cells were stimulated with AT1-receptor antibodies in the presence or absence of AT1-receptor blocker or AT2-receptor blocker. Protein extraction, sodium dodecyl sulfate–poly-acrylamide-gel electrophoresis, and membrane treatment were performed as described by Dechend et al.14 Primary antibodies against polyclonal extracellular signal–regulated kinase (ERK) 1/2 and phosphorylated ERK 1/2 were used. Triplicate experiments with six patients' IgG preparations were performed. Electromobility-shift assays in vascular smooth-muscle cells stimulated with angiotensin II, AT1-receptor antibodies, or control IgG were performed as described previously.14
Animal Model of Kidney Transplantation
The low-responder Fischer 344-to-Lewis life supporting rat kidney-transplantation model was used to test the physiological effects of various antibodies. AT1-receptor antibodies (a pool derived from two donors), control IgG, or vehicle was continuously infused into recipient rats by means of intraperitoneal, seven-day-release, osmotic minipumps (Alzet, Charles River Laboratories). After implantation of the minipumps, one kidney was transplanted into each rat (cold-ischemia time was two hours), and kidneys were harvested after seven days (n=4 per treatment group).15 For continuous blood-pressure monitoring, telemetric transmitters were placed into the abdominal aortas of six additional rodent recipients, before transplantation. The histologic features of the rat allografts were analyzed after harvesting with standard techniques. Direct immunofluorescence with fluorescein isothiocyanate–labeled antihuman IgG (Dako) was used to determine intragraft binding of AT1-receptor antibodies; cryosections were counterstained with 4',6-diamidino-2-phenylindole dihydrochloride (Vector).
Statistical Analysis
Continuous data are presented as medians (with ranges). We performed comparisons between groups with use of Fisher's exact test for categorical values and the Mann–Whitney U test for continuous variables.
Results
Thirty-three patients with steroid-refractory rejection were identified (23 at Charité University Hospital Campus Mitte and 10 at collaborating centers). Thirteen had detectable donor-specific anti-HLA antibodies. Sixteen patients who did not have donor-specific anti-HLA antibodies had malignant hypertension, followed by convulsions in four. Four patients had neither donor-specific anti-HLA antibodies nor malignant hypertension. Figure 1Figure 1
Features of Refractory Rejection in Patients without Donor-Specific Anti-HLA Antibodies. shows representative biopsy specimens from patients with malignant hypertension and refractory rejection who had no donor-specific anti-HLA antibodies; these showed either endarteritis (Figure 1A) or fibrinoid necrosis (Figure 1B). Patients whose biopsy specimens had evidence of fibrinoid necrosis underwent magnetic resonance angiography studies that showed multiple perfusion defects consistent with cortical infarctions (Figure 1C). Subsequently, patients with anti-HLA antibodies had substantially better graft survival than did those who had malignant hypertension but did not have anti-HLA antibodies (Figure 1D).We studied the AT1-receptor agonistic response and IgG subclasses with a bioassay that records the chronotropic response (the increase in the number of beats per minute) of spontaneously beating neonatal-rat cardiomyocytes when exposed to immunoglobulin from patients. Analysis of serum obtained from the 13 anti-HLA–positive patients and from the 16 anti-HLA–negative patients with malignant hypertension before transplantation and at the time of rejection indicated differences between the groups. Figure 2AFigure 2
Antibody Detection and Agonistic Activity as Indicated by a Bioassay Based on the Chronotropic Response of Neonatal-Rat Cardiomyocytes, Measured by the Increase in Beats per Minute. demonstrates a mean increase of 26 to 30 beats per minute in cells exposed to IgG obtained before transplantation or at the time of rejection from patients without anti-HLA antibodies. Serum from 13 patients with humoral rejection mediated by donor-specific anti-HLA antibodies did not induce such increases. Immunoglobulin from the four remaining patients, who had steroid-refractory rejection without malignant hypertension or HLA-antibodies, did not induce a response (data not shown).All 16 patients whose serum led to an increased chronotropic response were screened for hereditary and autoimmune causes of thrombophilia as a possible trigger of the observed thrombotic angiopathy; all tests were negative, as were additional serologic tests for autoimmune disorders. Acute infection with cytomegalovirus was ruled out by pp65 antigen and reverse-transcriptase polymerase-chain-reaction analysis (in three participating German centers) or on clinical grounds (in Bergamo, Italy).
Specific angiotensin II–receptor antagonists were used to test whether the agonistic response to patients' IgG was specific for the AT1 receptor. Losartan, but not the AT2-receptor antagonist PD 123319, abolished the functional bioassay response (Figure 2B). Angiotensin II and IgG from patients achieved results in the bioassay. Thus, IgG fractions of our patients' serum contained AT1-receptor antibodies.
The demographic data from the 16 patients who were positive for AT1-receptor antibodies were compared with those for the 13 patients with donor-specific anti-HLA-antibodies. As shown in Table 1Table 1
Characteristics of Patients with AT1-Receptor Antibodies and Patients with Donor-Specific Anti-HLA Antibodies but without AT1-Receptor Antibodies., patients with anti-HLA antibodies were more likely to have staining for C4d in their renal-biopsy specimens and had less rapid allograft loss. Otherwise, there were no significant differences in clinical or demographic characteristics between the two groups.To estimate the incidence and prevalence of steroid-refractory allograft rejections in patients with AT1-receptor antibodies, we studied all episodes of rejection that occurred after the 278 consecutive kidney transplantations performed at the Charité University Hospital Campus Mitte in Berlin between January 1, 2000, and July 31, 2004. During this period, 119 biopsy-proved episodes of rejection were treated; 23 were refractory to steroids (19.3 percent of all rejection episodes). Rejection in patients with donor-specific anti-HLA-antibodies accounted for 9 (39.1 percent) of the 23 steroid-refractory rejection episodes (7.6 percent of all rejection episodes).
In comparison, rejections in association with AT1-receptor antibodies had a similar incidence (10 episodes, accounting for 43.5 percent of steroid-refractory rejection episodes and 8.4 percent of all rejection episodes). The remaining four steroid-refractory rejection episodes at Charité Campus Mitte (accounting for 17.4 percent of steroid-refractory episodes and 3.4 percent of all rejection episodes) occurred in patients who had neither AT1-receptor antibodies nor donor-specific anti-HLA antibodies. The crude prevalence of the rejection episodes associated with AT1-receptor antibodies (10 among 278 kidney transplantations performed) during four years was 3.6 percent.
IgG fractions possessing agonistic activity were used to examine possible epitopes on the second extracellular loop of the AT1 receptor, to which the antibodies would bind. Two amino acid sequences, AFHYESQ and ENTNIT, inhibited the agonistic activity of IgG obtained from the patients (Figure 2C), indicating that these sites contain the IgG-binding epitopes for the antibody. Neutralization experiments in which monoclonal antihuman IgG1, IgG2, IgG3, and IgG4 antibodies were added to AT1-receptor antibodies demonstrated that antibodies of the IgG1 and IgG3 subclass are responsible for the agonist-like effect of these antibodies (Figure 2D).
The specificity of the bioassay findings was assessed with surface-plasmon-resonance analysis, which confirmed binding of AT1-receptor antibodies to the peptide of the second extracellular loop of the AT1 receptor. The BIA evaluation program used to analyze the results calculated the dissociation rate constant at 1.05±0.29×10–3 per second and the pseudomolecular association rate constant at 5.02±1.40×10–3 per second, revealing a high binding affinity of AT1-receptor antibodies to the AT1 receptor.
Thus, IgG fractions from patients contained AT1-receptor antibodies of the IgG1 and IgG3 subclasses that bound to the second extracellular loop of the AT1 receptor. Further studies were performed, on the basis of our hypothesis that these antibodies played a role in the pathogenesis of refractory vascular rejection. Vascular lesions in grafts that are rejected because of the presence of anti-HLA antibodies are generally attributed to complement activation. However, patients with AT1-receptor antibodies did not have complement-fixing cytotoxic anti-HLA antibodies in their serum, and their renal-biopsy specimens generally did not show staining for C4d. AT1-receptor antibodies were examined to see whether they could initiate signaling mediated by ERK 1/2 in vitro by means of endothelial cells and vascular smooth-muscle cells (Figure 3AFigure 3
ERK 1/2 Phosphorylation in Endothelial Cells and Vascular Smooth-Muscle Cells and AP-1 and NF-κB Activity in Vascular Smooth-Muscle Cells Stimulated with Angiotensin II and Patients' AT1-Receptor Antibodies. and Figure 3B). AT1-receptor antibody induced phosphorylation of ERK 1/2 (Figure 3A and Figure 3B), which peaked at 10 minutes without a change in total ERK 1/2 in the cells.We also examined the possibility that the AT1-receptor antibodies could activate the transcription factor activator protein 1 (AP-1) down-stream from ERK 1/2 (Figure 3C). Both AT1-receptor antibodies and angiotensin II itself induced AP-1 activity in vascular smooth-muscle cells, whereas control IgG caused no such induction. DNA-binding activity of nuclear factor-κB (NF-κB), a transcription factor pivotal in initiating immune responses and inflammatory disease,16 when studied in nuclear extracts from vascular smooth-muscle cells, was activated by AT1-receptor antibodies, but not by IgG from control patients (Figure 3D).
Tissue factor, which initiates the extrinsic coagulation pathway, is a target gene for AP-1 and NF-κB. Biopsy specimens obtained from patients during episodes of rejection mediated by AT1-receptor antibodies revealed intense staining of tubular cells, inflammatory infiltrate, and peritubular capillaries (Figure 4AFigure 4
Influence of Losartan and Plasmapheresis Treatment on Tissue-Factor Expression, Allograft Survival, and AT1-Receptor–Antibody Activity in AT1-Receptor–Antibody–Positive Rejection.). In contrast, only weakly positive staining was seen in biopsy specimens obtained after patients had been treated with losartan and plasmapheresis (Figure 4B). Treatment consisting of plasmapheresis, intravenous immune globulin, and 100 mg of losartan daily in seven patients with AT1-receptor antibodies resulted in significantly improved allograft survival, as compared with that in patients receiving standard antirejection treatment (Figure 4C). Serum from four patients with the longest rejection-free follow-up (who are still receiving losartan) became negative for AT1-receptor antibodies (Figure 4D).To demonstrate that the agonistic antibodies could induce vascular rejection, AT1-receptor antibodies were infused into rats that had received kidney transplants. One week after transplantation, kidneys from all experimental animals showed evidence of endarteritis and intravascular infiltrates (Figure 5AFigure 5
Induction of Acute Vascular Rejection in Transplant-Recipient Rats Treated with Human AT1-Receptor Antibodies and Immunostaining for Human AT1-Receptor Antibodies in Injured Vascular Media.). Transplants from control animals infused with control IgG showed only endothelial activation (Figure 5B). Infusion of AT1-receptor antibodies had no effect on native kidneys in uninephrectomized animals (data not shown). The act of transplanting non-native kidneys into recipients appeared to make the organs prone to the effects of AT1-receptor antibodies. AT1-receptor antibodies containing human AT1-receptor–activating antibody–positive IgG but not control IgG could be detected within the muscular layer of injured arteries in the rats (Figure 5C and Figure 5D). The mean arterial pressure, measured by radiotelemetry, was higher in the group of rats with AT1-receptor antibodies two weeks after transplantation than in controls (Figure 5E).Discussion
Patients with refractory vascular allograft rejection and accelerated hypertension but without anti-HLA antibodies were found to have pathogenic antibodies directed at two epitopes of the second extracellular loop of the AT1 receptor in their serum. AT1-receptor antibodies induced phosphorylation of ERK 1/2, AP-1 activation, and NF-κB activation in vascular cells. An AT1-receptor antagonist blocked the effects mediated by AT1-receptor antibodies. Passive infusion of AT1-receptor antibodies in a rat renal-transplantation model induced vascular changes and increased blood pressure. These data suggest that AT1-receptor antibodies may be directly involved in the pathogenesis of vascular rejection.
Earlier we had observed AT1-receptor activity during steroid-refractory, C4d-negative renal-allograft rejection in nine patients with hypertension, but not in eight patients with steroid-sensitive cellular rejection. In the present study, we increased the number of patients studied and clearly defined the pretransplantation activity of IgG1- and IgG3-subclass antibodies that bound to AT1-receptor epitopes and induced signaling cascades. The clinical presentation of transplant recipients with AT1-receptor antibodies appears similar to that of transplant recipients with anti-HLA antibodies, but with significantly worse allograft survival.
Similar agonistic antibodies against the AT1 receptor have been reported in patients with preeclampsia.7 Recently, other investigators confirmed the existence of AT1-receptor antibodies in patients with preeclampsia17 and also demonstrated that the antibodies induced mobilization of intracellular calcium and activation of a transcription factor, nuclear factor of activated T cells, in AT1-receptor–transfected Chinese-hamster-ovary cells.17 The index patient in the present report had had preeclampsia many years earlier. Nevertheless, the antibodies in this patient and the other transplant recipients bound to an epitope that did not entirely coincide with the antibodies described earlier in the patients with preeclampsia.7
Antibodies to G-protein receptors have been identified in some patients with idiopathic dilated cardiomyopathy18 or malignant hypertension.19 In Graves' disease, autoantibodies activate the thyrotropin G-protein receptor, increasing target-organ activity.20 Anti–endothelial-cell antibodies are non-HLA antibodies that may be related to the pathogenesis of allograft rejection.21,22 However, research on anti–endothelial-cell antibodies is hampered by the heterogeneity of endothelial cells in various vascular beds, a fact that makes identifying a standard detection method difficult.23 Moreover, initially detected target antigens of anti–endothelial-cell antibodies were of unclear relevance.23
We suggest that AT1-receptor antibodies have similarities to anti–endothelial-cell antibodies since endothelial cells have one AT1 receptor,24 and AT1-receptor antibodies induced phosphorylation of ERK 1/2 in endothelial cells. We further suggest that binding of AT1-receptor antibodies to the AT1 receptor is a critical step for activating the downstream signaling cascade, mimicking the action of angiotensin II and inducing damage to the allograft. Emerging information has established that angiotensin II acts as an inflammatory cytokine participating in various vascular disorders.25
AT1-receptor antibodies may induce inflammatory responses and contribute to allograft rejection by means of activation of NF-κB target genes. Blockade of NF-κB activity with decoy oligodeoxynucleotides reduced tubulointerstitial infiltration in rat renal allografts.26 Expression of tissue factor as regulated by NF-κB and AP-1 may increase procoagulatory activity of the injured vessels.
We previously reported NF-κB and AP-1 subunit expression in biopsy specimens from several kidney-transplant recipients.8 We now report that biopsy specimens of patients with rejection associated with AT1-receptor antibodies had evidence of increased tissue factor expression and secondary thrombotic occlusions and that tissue factor was reduced after losartan treatment. It has previously been recognized that the coagulation system has a role in the pathogenesis of rejection.27 An anticardiolipin antibody–mediated increase in tissue factor expression contributes to thrombosis in patients with the antiphospholipid syndrome.28 In rat cardiac allografts, tissue factor plays a critical role in clotting abnormalities and transplant arteriosclerosis.29 Lesions in allografts in rats infused with AT1-receptor antibodies resemble those observed in kidney-transplant recipients.
It is unknown whether AT1-receptor antibodies function only through proinflammatory and procoagulatory activity or also by means of specific immune responses. Experimental studies have implicated the renin–angiotensin system in the regulation of the specific immune response and immune-mediated renal injury.30,31 Since AT1 receptors are present on human mononuclear cells,32,33 an effect of AT1-receptor antibodies on T lymphocytes, monocytes, and dendritic cells appears to be likely. Furthermore, rejection in association with circulating anti-HLA antibodies is commonly characterized by a high incidence of severe vascular lesions with fibrinoid necrosis, whereas endarteritis and mononuclear cell tubulitis predominate in T-cell–mediated rejection.34
We first observed endarteritis and later fibrinoid necrosis, tubulitis, and interstitial-cell infiltration in patients' biopsy specimens. These characteristics may define a distinct type of kidney-transplant rejection mediated by AT1-receptor antibodies. The incidence of rejection among patients positive for AT1-receptor antibodies in this study is similar to that of rejection due to donor-specific anti-HLA antibodies. However, it remains unclear why AT1-receptor antibodies develop in certain patients and why these antibodies target the allograft.
Molecular mimicry may be important; cross-reactivity with microbial antigens has an important role in other pathologic processes associated with antibodies directed against G-protein receptors — for example, myasthenia gravis or the dilated cardiomyopathy seen in Chagas' disease.35,36 We have not tested the possibility that the AT1 receptors in patients in whom AT1-receptor antibodies develop might harbor specific polymorphisms.37 We speculate that post-transplantation reperfusion injury may alter the intragraft expression of AT1 receptor, change its density, or cause conformational changes. A permissive environmental phenomenon might enhance local intragraft immunoreactivity owing to an activated innate immune response.
Transplantation nephrologists have been reluctant to use angiotensin II blockers because of possible decreases in organ perfusion and filtration. However, this concern may be outweighed by the potential advantages of these drugs.38 The seven patients discussed here who were treated with losartan, plasmapheresis, and intravenous immunoglobulin had amelioration of the antibody-mediated rejection process and remain free of rejection while receiving losartan. However, their treatment was neither randomly assigned nor blinded, and the numbers of patients are too small to permit us to draw firm conclusions. We speculate that detection of AT1-receptor antibodies in patients on a waiting list for a transplant might identify those at risk for refractory rejection.
Dr. Fritsche reports having served as a consultant to Novartis, Hexal, Shire, and GDL, being a stockholder in Novartis, receiving grant support from Novartis and Wyeth, and receiving lecture fees from Hoffmann–La Roche. Dr. Kintscher reports having served on the advisory boards of Novartis and Takeda, receiving grant support from Boehringer Ingelheim, and receiving lecture fees from Takeda. Dr. Unger reports serving as a consultant to Novartis, Abbott, Takeda, and Merck and having received grant support from Takeda, Novartis, Bayer, and Boehringer Ingelheim. Dr. Neumayer reports having received consulting fees from Novartis and Shire and lecture fees from Novartis and Wyeth. Dr. Luft reports having served as a consultant and receiving grant support from Novartis, Boehringer Ingelheim, and CVRx.
We are indebted to Professor U. Frei of Humboldt University in Berlin, Professor G. Remuzzi and Dr. N. Perico of the Mario Negri Institute in Bergamo, Italy, and Professor K. Amann and Dr. C. Hugo of the University of Nürnberg–Erlangen for providing samples.
Source Information
From the Departments of Nephrology (D.D., L.F., M.N.-K., D.E., K.B., H.-H.N.) and Pathology (B.R.), and the Center for Cardiovascular Research (D.D., M.N.-K., U.K., T.U.), Charité University Hospital; the Franz Volhard Clinic and HELIOS Klinikum (J.H.B., R.D., I.M., F.C.L.); the Max Delbrück Center for Molecular Medicine (D.N.M., R.P., G.W.); and the HLA Laboratory (C.S.) — all in Berlin; and the Institut de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Strasbourg, France (J.H.).
Address reprint requests to Dr. Dragun at the Department of Nephrology and Transplantation, Charité University Hospital, Campus Mitte, Schumannstr. 20–21, 10117 Berlin, Germany, or at duska.dragun@charite.de.
- References
References
1
van Saase J ,van der Woude FJ ,Thorogood J , et al. The relation between acute vascular and interstitial renal allograft rejection and subsequent chronic rejection. Transplantation 1995;59:1280-1285
Web of Science | Medline2
Jeannet M ,Pinn VW ,Flax MH ,Winn HJ ,Russell PS . Humoral antibodies in renal allotransplantation in man. N Engl J Med 1970;282:111-117
Full Text | Web of Science | Medline3
Ahern AT ,Artruc SB ,DellaPelle P , et al. Hyperacute rejection of HLA-AB-identical renal allografts associated with B lymphocytes and endothelial reactive antibodies. Transplantation 1982;33:103-106
CrossRef | Web of Science | Medline4
Yard B ,Spruyt-Gerritse M ,Claas F , et al. The clinical significance of allospecific antibodies against endothelial cells detected with an antibody-dependent cellular cytotoxicity assay for vascular rejection and graft loss after renal transplantation. Transplantation 1993;55:1287-1293
CrossRef | Web of Science | Medline5
Le Bas-Bernardet S ,Hourmant M ,Coupel S ,Bignon JD ,Soulillou JP ,Charreau B . Non-HLA-type endothelial cell reactive alloantibodies in pre-transplant sera of kidney recipients trigger apoptosis. Am J Transplant 2003;3:167-177
CrossRef | Web of Science | Medline6
Mellor AL ,Munn DH . Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression. Annu Rev Immunol 2000;18:367-391
CrossRef | Web of Science | Medline7
Wallukat G ,Homuth V ,Fischer T , et al. Patients with preeclampsia develop agonistic antibodies against the angiotensin AT1 receptor. J Clin Invest 1999;103:945-952
CrossRef | Web of Science | Medline8
Dragun D ,Brasen JH ,Schonemann C , et al. Patients with steroid refractory acute vascular rejection develop agonistic antibodies targeting angiotensin II type 1 receptor. Transplant Proc 2003;35:2104-2105
CrossRef | Web of Science | Medline9
Racusen LC ,Solez K ,Colvin RB , et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999;55:713-723
CrossRef | Web of Science | Medline10
Racusen LC ,Colvin RB ,Solez K , et al. Antibody-mediated rejection criteria -- an addition to the Banff 97 classification of renal allograft rejection. Am J Transplant 2003;3:708-714
CrossRef | Web of Science | Medline11
Bohmig G ,Exner M ,Habicht A , et al. Capillary C4d deposition in kidney allografts: a specific marker of alloantibody-dependent graft injury. J Am Soc Nephrol 2002;13:1091-1099
Web of Science | Medline12
Regele H ,Exner M ,Watschinger B , et al. Endothelial C4d deposition is associated with inferior kidney allograft outcome independently of cellular rejection. Nephrol Dial Transplant 2001;16:2058-2066
CrossRef | Web of Science | Medline13
Wallukat G ,Wollenberger A ,Morwinski R ,Pitschner HF . Anti-β1-adrenoreceptor autoantibodies with chronotropic activity from the serum of patients with dilated cardiomyopathy: mapping of epitopes in the first and second extracellular loops. J Mol Cell Cardiol 1995;27:397-406[Erratum, J Mol Cell Cardiol 1995;27:2529.]
CrossRef | Web of Science | Medline14
Dechend R ,Homuth V ,Wallukat G , et al. AT(1) receptor agonistic antibodies from preeclamptic patients cause vascular cells to express tissue factor. Circulation 2000;101:2382-2387
Web of Science | Medline15
Dragun D ,Hoff U ,Park JK , et al. Ischemia-reperfusion injury in renal transplantation is independent of the immunologic background. Kidney Int 2000;58:2166-2177
CrossRef | Web of Science | Medline16
Baeuerle P . IκB-NF-κB structures: at the interface of inflammation control. Cell 1998;95:729-731
CrossRef | Web of Science | Medline17
Thway TM ,Shlykov SG ,Day MC , et al. Antibodies from preeclamptic patients stimulate increased intracellular Ca2+ mobilization through angiotensin receptor activation. Circulation 2004;110:1612-1619
CrossRef | Web of Science | Medline18
Magnusson Y ,Wallukat G ,Waagstein F ,Hjalmarson A ,Hoebeke J . Autoimmunity in idiopathic dilated cardiomyopathy: characterization of antibodies against the beta1-adrenoceptor with positive chronotropic effect. Circulation 1994;89:2760-2767
Web of Science | Medline19
Fu ML ,Herlitz H ,Wallukat G , et al. Functional autoimmune epitope on α1-adrenergic receptors in patients with malignant hypertension. Lancet 1994;344:1660-1663
CrossRef | Web of Science | Medline20
Rapaport B ,McLachlan SM . Thyroid autoimmunity. J Clin Invest 2001;108:1253-1259
Web of Science | Medline21
Paul LC ,Baldwin WM III ,van Es LA . Vascular endothelial alloantigens in renal transplantation. Transplantation 1985;40:117-123
CrossRef | Web of Science | Medline22
van der Woude FJ ,Deckers JGM ,Mallat MJK , et al. Tissue antigens in tubulointerstitial and vascular rejection. Kidney Int 1995;52:Suppl:S11-S1323
Praprotnik S ,Blank M ,Meroni PL ,Rozman B ,Eldor A ,Shoenfeld Y . Classification of anti-endothelial cell antibodies into antibodies against microvascular and macrovascular endothelial cells: the pathogenic and diagnostic implications. Arthritis Rheum 2001;44:1484-1494
CrossRef | Web of Science | Medline24
de Gasparo M ,Catt KJ ,Inagami T ,Wright JW ,Unger T . International Union of Pharmacology: XXIII. The angiotensin II receptors. Pharmacol Rev 2000;52:415-472
Web of Science | Medline25
Ruiz-Ortega M ,Lorenzo O ,Suzuki Y ,Ruperez M ,Egido J . Proinflammatory actions of angiotensins. Curr Opin Nephrol Hypertens 2001;10:321-329
CrossRef | Web of Science | Medline26
Vos IH ,Govers S ,Grone HJ , et al. NF-κB decoy oligodeoxynucleotides reduce monocyte infiltration in renal allografts. FASEB J 2000;14:815-822
Web of Science | Medline27
Heidenreich S ,Dercken C ,August C ,Koch HG ,Nowak-Gottl U . High rate of acute rejections in renal allograft recipients with thrombophilic risk factors. J Am Soc Nephrol 1998;9:1309-1313
Web of Science | Medline28
Dobado-Berrios P ,Lopez-Pedrera C ,Velasco F ,Cuadrado MJ . The role of tissue factor in the antiphospholipid syndrome. Arthritis Rheum 2001;44:2467-2476
CrossRef | Web of Science | Medline29
Holschermann H ,Bohle RM ,Zeller H , et al. In situ detection of tissue factor within the coronary intima in rat cardiac graft vasculopathy. Am J Pathol 1999;154:211-220
CrossRef | Web of Science | Medline30
Hisada Y ,Sugaya T ,Yamanouchi M , et al. Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 1999;103:627-635
CrossRef | Web of Science | Medline31
Nataraj C ,Oliverio M ,Mannon RB , et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999;104:1693-1701
CrossRef | Web of Science | Medline32
Shimada K ,Yazaki Y . Binding sites for angiotensin II in human mononuclear leucocytes. J Biochem (Tokyo) 1978;84:1013-1015
Web of Science | Medline33
Nahmod KA ,Vermeulen ME ,Raiden S , et al. Control of dendritic cell differentiation by angiotensin II. FASEB J 2003;17:491-493
Web of Science | Medline34
Mauiyyedi S ,Crespo M ,Collins AB , et al. Acute humoral rejection in kidney transplantation: II. Morphology, immunopathology, and pathologic classification. J Am Soc Nephrol 2002;13:779-787
Web of Science | Medline35
Schwimmbeck PL ,Dyrberg T ,Drachman DB ,Oldstone MB . Molecular mimicry and myasthenia gravis: an autoantigenic site of the acetylcholine receptor α-subunit that has biologic activity and reacts immunochemically with herpes simplex virus. J Clin Invest 1989;84:1174-1180
CrossRef | Web of Science | Medline36
Masuda MO ,Levin M ,De Oliveira SF , et al. Functionally active cardiac antibodies in chronic Chagas' disease are specifically blocked by Trypanosoma cruzi antigens. FASEB J 1998;12:1551-1558
Web of Science | Medline37
Miller JA ,Thai K ,Scholey JW . Angiotensin II type 1 receptor gene polymorphism predicts response to losartan and angiotensin II. Kidney Int 1999;56:2173-2180
CrossRef | Web of Science | Medline38
Remuzzi G ,Perico N . Routine renin-angiotensin system blockade in renal transplantation? Curr Opin Nephrol Hypertens 2002;11:1-10
CrossRef | Web of Science | Medline
- Citing Articles (134)
Citing Articles
1
A. M. Jackson, M. B. Kuperman, R. A. Montgomery. (2012) Multiple Hyperacute Rejections in the Absence
of Detectable Complement Activation in a Patient
CrossRef2
Stefan Verlohren, Holger Stepan, Ralf Dechend. (2012) Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clinical Science 122:2, 43-52
CrossRef3
T. Shimizu, T. Tanabe, K. Omoto, H. Ishida, K. Tanabe. (2012) Clinicopathologic Analysis of Acute Vascular Rejection Cases After Renal Transplantation. Transplantation Proceedings 44:1, 230-235
CrossRef4
Christos Chatzikyrkou, Jan Menne, Wilfried Gwinner, Bernhard M. Schmidt, Frank Lehner, Cornelia Blume, Anke Schwarz, Hermann Haller, Mario Schiffer. (2011) Pathogenesis and management of hypertension after kidney transplantation. Journal of Hypertension 29:12, 2283-2294
CrossRef5
Maddalena Marasà, Giuseppe Remuzzi, Paolo Cravedi. (2011) Hypertension after kidney transplantation. Journal of Hypertension 29:12, 2310-2311
CrossRef6
Gregor Bartel, Elisabeth Schwaiger, Georg A. Böhmig. (2011) Prevention and treatment of alloantibody-mediated kidney transplant rejection. Transplant International 24:12, 1142-1155
CrossRef7
Venkataswarup Tiriveedhi, Andrew E. Gelman, T. Mohanakumar. (2011) HIF-1α signaling by airway epithelial cell K-α1-tubulin: Role in fibrosis and chronic rejection of human lung allografts. Cellular Immunology
CrossRef8
Reinhard Kelsch, Anne Schulze Everding, Eberhard Kuwertz-Bröking, Eva Brand, Bernd M. Spriewald, Walter Sibrowski, Martin Konrad, Duska Dragun. (2011) Accelerated Kidney Transplant Rejection and Hypertensive Encephalopathy in a Pediatric Patient Associated With Antibodies Against Angiotensin Type 1 Receptor and HLA Class II. Transplantation 92:10, e57-e59
CrossRef9
R. Neal Smith, Robert B. Colvin. (2011) Chronic alloantibody mediated rejection. Seminars in Immunology
CrossRef10
Z. Jin, J. Wang, W. Zhang, G. Zhang, X. Jiao, J. Zhi. (2011) Changes in cardiac structure and function in rats immunized by angiotensin type 1 receptor peptides. Acta Biochimica et Biophysica Sinica
CrossRef11
P. Gatault, I. Jollet, N. Rabot, M. D. Boulanger, J. L. Taupin, C. Barbet, C. Baron, A. Thierry, J. M. Halimi, Y. Lebranchu, G. Touchard, M. Büchler. (2011) Mothers without HLA antibodies before transplantation have a low risk of alloimmunization post-transplantation. Tissue Antigens 78:4, 241-248
CrossRef12
Yang Xia, Rodney E Kellems. (2011) Receptor-activating autoantibodies and disease: preeclampsia and beyond. Expert Review of Clinical Immunology 7:5, 659-674
CrossRef13
Matthew R. Weir, Daniel J. Salzberg. (2011) Management of hypertension in the transplant patient. Journal of the American Society of Hypertension 5:5, 425-432
CrossRef14
Cécile Taflin, Dominique Charron, Denis Glotz, Nuala Mooney. (2011) Immunological function of the endothelial cell within the setting of organ transplantation. Immunology Letters 139:1-2, 1-6
CrossRef15
J. Waiser, K. Budde, M. Schutz, L. Liefeldt, B. Rudolph, C. Schonemann, H.-H. Neumayer, N. Lachmann. (2011) Comparison between bortezomib and rituximab in the treatment of antibody-mediated renal allograft rejection. Nephrology Dialysis Transplantation
CrossRef16
B. L. Laskin, J. Goebel, S. M. Davies, S. Jodele. (2011) Small vessels, big trouble in the kidneys and beyond: hematopoietic stem cell transplantation-associated thrombotic microangiopathy. Blood 118:6, 1452-1462
CrossRef17
Robert A. Montgomery, Emanuele Cozzi, Lori J. West, Daniel S. Warren. (2011) Humoral immunity and antibody-mediated rejection in solid organ transplantation. Seminars in Immunology 23:4, 224-234
CrossRef18
Asami Takeda, Keiji Horike, Yasuhiro Ohtsuka, Daijo Inaguma, Norihiko Goto, Yoshihiko Watarai, Kazuharu Uchida, Kunio Morozumi. (2011) Current problems of chronic active antibody-mediated rejection. Clinical Transplantation 25, 2-5
CrossRef19
Annette M. Jackson, Donna P. Lucas, J. Keith Melancon, Niraj M. Desai. (2011) Clinical Relevance and IgG Subclass Determination of Non-HLA Antibodies Identified Using Endothelial Cell Precursors Isolated From Donor Blood. Transplantation 92:1, 54-60
CrossRef20
Sebastiaan Heidt, David San Segundo, Sushma Shankar, Shruti Mittal, Anand S.R. Muthusamy, Peter J. Friend, Susan V. Fuggle, Kathryn J. Wood. (2011) Peripheral Blood Sampling for the Detection of Allograft Rejection: Biomarker Identification and Validation. Transplantation 92:1, 1-9
CrossRef21
Brian B. Borg, Anil Seetharam, Vijay Subramanian, Haseeb Ilias Basha, Mauricio Lisker-Melman, Kevin Korenblat, Christopher D. Anderson, Surendra Shenoy, William C. Chapman, Jeffrey S. Crippin, Thalachallour Mohanakumar. (2011) Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis. Liver Transplantation 17:7, 814-823
CrossRef22
Deepti Saini, Joseph Weber, Sabarinathan Ramachandran, Donna Phelan, Venkataswarup Tiriveedhi, Michael Liu, Nancy Steward, Aviva Aloush, Ramsey Hachem, Elbert Trulock, Bryan Meyers, G. Alexander Patterson, Thalachallour Mohanakumar. (2011) Alloimmunity-induced autoimmunity as a potential mechanism in the pathogenesis of chronic rejection of human lung allografts. The Journal of Heart and Lung Transplantation 30:6, 624-631
CrossRef23
Patrizia Amico, Patricia Hirt-Minkowski, Gideon Hönger, Lorenz Gürke, Michael J Mihatsch, Jürg Steiger, Helmut Hopfer, Stefan Schaub. (2011) Risk stratification by the virtual crossmatch: a prospective study in 233 renal transplantations. Transplant International 24:6, 560-569
CrossRef24
Qiuheng Zhang, J. Michael Cecka, David W. Gjertson, Ping Ge, Marlene L. Rose, Jignesh K. Patel, Abbas Ardehali, Jon A. Kobashigawa, Michael C. Fishbein, Elaine F. Reed. (2011) HLA and MICA: Targets of Antibody-Mediated Rejection in Heart Transplantation. Transplantation 91:10, 1153-1158
CrossRef25
Feng Zhu, Yanxiang Sun, Min Wang, Shihui Ma, Xiao Chen, Ailin Cao, Fen Chen, Yan Qiu, Yuhua Liao. (2011) Correlation Between HLA-DRB1, HLA-DQB1 Polymorphism and Autoantibodies Against Angiotensin AT1 Receptors in Chinese Patients With Essential Hypertension. Clinical Cardiology 34:5, 302-308
CrossRef26
Babbette LaMarca, Kedra Wallace, Joey Granger. (2011) Role of angiotensin II type I receptor agonistic autoantibodies (AT1-AA) in preeclampsia. Current Opinion in Pharmacology 11:2, 175-179
CrossRef27
Qiquan Sun, Zhen Cheng, Dongrui Cheng, Jinsong Chen, Shuming Ji, Jiqiu Wen, Chunxia Zheng, Zhihong Liu. (2011) De novo development of circulating anti-endothelial cell antibodies rather than pre-existing antibodies is associated with post-transplant allograft rejection. Kidney International 79:6, 655-662
CrossRef28
Jessica G Lucas, Jeannie P Co, Uzoamaka T Nwaogwugwu, Imran Dosani, Kalathil K Sureshkumar. (2011) Antibody-mediated rejection in kidney transplantation: an update. Expert Opinion on Pharmacotherapy 12:4, 579-592
CrossRef29
Mahendra Mangray, John P. Vella. (2011) Hypertension After Kidney Transplant. American Journal of Kidney Diseases 57:2, 331-341
CrossRef30
Tom Cornelis, Ayodele Odutayo, Johannes Keunen, Michelle Hladunewich. (2011) The Kidney in Normal Pregnancy and Preeclampsia. Seminars in Nephrology 31:1, 4-14
CrossRef31
Silke Roedder, Matthew Vitalone, Purvesh Khatri, Minnie M Sarwal. (2011) Biomarkers in solid organ transplantation: establishing personalized transplantation medicine. Genome Medicine 3:6, 37
CrossRef32
Robert B Colvin, Tsutomu Hirohashi, Alton B Farris, Francesca Minnei, A Bernard Collins, R Neal Smith. (2010) Emerging role of B cells in chronic allograft dysfunction. Kidney International 78, S13-S17
CrossRef33
Roslyn B Mannon. (2010) Immune monitoring and biomarkers to predict chronic allograft dysfunction. Kidney International 78, S59-S65
CrossRef34
Paolo Cravedi, Norberto Perico, Giuseppe Remuzzi. (2010) Non-immune interventions to protect kidney allografts in the long term. Kidney International 78, S71-S75
CrossRef35
Nancy L. Reinsmoen, Chih-Hung Lai, Harald Heidecke, Mark Haas, Kai Cao, Geraldine Ong, Mehrnoush Naim, Qi Wang, James Mirocha, Joseph Kahwaji, Ashley A. Vo, Stanley C. Jordan, Duska Dragun. (2010) Anti-Angiotensin Type 1 Receptor Antibodies Associated With Antibody Mediated Rejection in Donor HLA Antibody Negative Patients. Transplantation 90:12, 1473-1477
CrossRef36
Schwartz, Robert S., , Nankivell, Brian J., Alexander, Stephen I., . (2010) Rejection of the Kidney Allograft. New England Journal of Medicine 363:15, 1451-1462
Full Text37
MR Clatworthy, M Espeli, N Torpey, KGC Smith. (2010) The generation and maintenance of serum alloantibody. Current Opinion in Immunology 22:5, 669-681
CrossRef38
Su-li Zhang, Yun-hui Du, Jin Wang, Li-hong Yang, Xiao-li Yang, Rong-hua Zheng, Ye Wu, Ke Wang, Ming-sheng Zhang, Hui-rong Liu. (2010) Endothelial dysfunction induced by antibodies against angiotensin AT1 receptor in immunized rats. Acta Pharmacologica Sinica 31:10, 1381-1388
CrossRef39
Qiuheng Zhang, Elaine F Reed. (2010) Non-MHC antigenic targets of the humoral immune response in transplantation. Current Opinion in Immunology 22:5, 682-688
CrossRef40
Marc R. Parrish, Sydney R. Murphy, Sarah Rutland, Kedra Wallace, Katrin Wenzel, Gerd Wallukat, Sharon Keiser, Lillian Fournier Ray, Ralf Dechend, James N. Martin, Joey P. Granger, Babbette LaMarca. (2010) The Effect of Immune Factors, Tumor Necrosis Factor-α, and Agonistic Autoantibodies to the Angiotensin II Type I Receptor on Soluble fms-Like Tyrosine-1 and Soluble Endoglin Production in Response to Hypertension During Pregnancy. American Journal of Hypertension 23:8, 911-916
CrossRef41
Venkataswarup Tiriveedhi, Nataraju Angaswamy, Joseph Weber, T. Mohanakumar. (2010) Lipid raft facilitated ligation of K-α1-tubulin by specific antibodies on epithelial cells: Role in pathogenesis of chronic rejection following human lung transplantation. Biochemical and Biophysical Research Communications 399:2, 251-255
CrossRef42
Gavin Pettigrew. (2010) Autoantibody and Transplant Vasculopathy: The Enemy Within. Transplantation 90:1, 2-3
CrossRef43
Thet Su Win, Gavin J. Pettigrew. (2010) Humoral Autoimmunity and Transplant Vasculopathy: When Allo is Not Enough. Transplantation 90:2, 113-120
CrossRef44
Tomokazu Shimizu, Hideki Ishida, Hiroki Shirakawa, Kazuya Omoto, Kuniko Tsunoyama, Tadahiko Tokumoto, Kazunari Tanabe. (2010) Clinicopathological analysis of acute vascular rejection cases after renal transplantation. Clinical Transplantation 24, 22-26
CrossRef45
Ariela Benigni, Paola Cassis, Giuseppe Remuzzi. (2010) Angiotensin II revisited: new roles in inflammation, immunology and aging. EMBO Molecular Medicine 2:7, 247-257
CrossRef46
Peter H. Hagedorn, Christopher M. Burton, Jørn Carlsen, Daniel Steinbrüchel, Claus B. Andersen, Eli Sahar, Eytan Domany, Irun R. Cohen, Henrik Flyvbjerg, Martin Iversen. (2010) Chronic rejection of a lung transplant is characterized by a profile of specific autoantibodies. Immunology 130:3, 427-435
CrossRef47
Balakrishnan Mahesh, Hon-Sing Leong, K. Sukumaran Nair, Ann McCormack, Padmini Sarathchandra, Marlene L. Rose. (2010) Autoimmunity to Vimentin Potentiates Graft Vasculopathy in Murine Cardiac Allografts. Transplantation 90:1, 4-13
CrossRef48
Bruce C. McLeod. (2010) Therapeutic apheresis: history, clinical application, and lingering uncertainties. Transfusion 50:7, 1413-1426
CrossRef49
D. Dragun, A. Philippe. (2010) From mother to child--transplacental effect of AT1R-AAin preeclampsia. Nephrology Dialysis Transplantation 25:6, 1774-1776
CrossRef50
Laurence H Beck, David J Salant. (2010) Membranous nephropathy: recent travels and new roads ahead. Kidney International 77:9, 765-770
CrossRef51
Fabrice Porcheray, Julie DeVito, Beow Y. Yeap, Lijuan Xue, Ian Dargon, Rosemary Paine, Timothy C. Girouard, Susan L. Saidman, Robert B. Colvin, Waichi Wong, Emmanuel Zorn. (2010) Chronic Humoral Rejection of Human Kidney Allografts Associates With Broad Autoantibody Responses. Transplantation 89:10, 1239-1246
CrossRef52
Brigitte A Wevers, Lia van der Hoek. (2010) Renin–angiotensin system in human coronavirus pathogenesis. Future Virology 5:2, 145-161
CrossRef53
M. Alheim, S. M. Johansson, D. Hauzenberger, P. Grufman, J. Holgersson. (2010) A flow cytometric crossmatch test for simultaneous detection of antibodies against donor lymphocytes and endothelial precursor cells. Tissue Antigens 75:3, 269-277
CrossRef54
Gary S Hill, Dominique Nochy, Alexandre Loupy. (2010) Accelerated arteriosclerosis: a form of transplant arteriopathy. Current Opinion in Organ Transplantation 15:1, 11-15
CrossRef55
Patrizia Amico, Gideon Hönger, Jürg Steiger, Stefan Schaub. (2009) Utility of the virtual crossmatch in solid organ transplantation. Current Opinion in Organ Transplantation 14:6, 656-661
CrossRef56
Hamid Rabb. (2009) Protein kinase Cζ: not-so-innocent bystander or unusual suspect in kidney transplant rejection?. Kidney International 76:12, 1223-1224
CrossRef57
F. Lühder, D.H. Lee, R. Gold, J. Stegbauer, R.A. Linker. (2009) Small but powerful: Short peptide hormones and their role in autoimmune inflammation. Journal of Neuroimmunology 217:1-2, 1-7
CrossRef58
A. Haririan, B. Kiangkitiwan, D. Kukuruga, M. Cooper, H. Hurley, C. Drachenberg, D. Klassen. (2009) The Impact of C4d Pattern and Donor-Specific Antibody on Graft Survival in Recipients Requiring Indication Renal Allograft Biopsy. American Journal of Transplantation 9:12, 2758-2767
CrossRef59
Scott M Sutherland, Li Li, Tara K Sigdel, Persis P Wadia, David B Miklos, Atul J Butte, Minnie M Sarwal. (2009) Protein microarrays identify antibodies to protein kinase Cζ that are associated with a greater risk of allograft loss in pediatric renal transplant recipients. Kidney International 76:12, 1277-1283
CrossRef60
Michael Bieri, Melinda Oroszlan, Anikò Farkas, Nathalie Ligeti, Jürg Bieri, Paul Mohacsi. (2009) Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. The International Journal of Biochemistry & Cell Biology 41:12, 2422-2430
CrossRef61
Muhammad A. Rafiq, Graciela de Boccardo, Bernd Schröppel, Jonathan S. Bromberg, Vinita Sehgal, Rajani Dinavahi, Barbara Murphy, Enver Akalin. (2009) Differential outcomes in 3 types of acute antibody-mediated rejection. Clinical Transplantation 23:6, 951-957
CrossRef62
X. Zhang, E. F. Reed. (2009) Effect of Antibodies on Endothelium. American Journal of Transplantation 9:11, 2459-2465
CrossRef63
J. Stegbauer, D.-H. Lee, S. Seubert, G. Ellrichmann, A. Manzel, H. Kvakan, D. N. Muller, S. Gaupp, L. C. Rump, R. Gold, R. A. Linker. (2009) Role of the renin-angiotensin system in autoimmune inflammation of the central nervous system. Proceedings of the National Academy of Sciences 106:35, 14942-14947
CrossRef64
F. Porcheray, W. Wong, S. L. Saidman, J. De Vito, T. C. Girouard, M. Chittenden, J. Shaffer, N. Tolkoff-Rubin, B. R. Dey, T. R. Spitzer, R. B. Colvin, A. B. Cosimi, T. Kawai, D. H. Sachs, M. Sykes, E. Zorn. (2009) B-Cell Immunity in the Context of T-Cell Tolerance after Combined Kidney and Bone Marrow Transplantation in Humans. American Journal of Transplantation 9:9, 2126-2135
CrossRef65
P. Hempel, P. Karczewski, K.-D. Kohnert, J. Raabe, B. Lemke, R. Kunze, M. Bimmler. (2009) Sera from Patients with Type 2 Diabetes Contain Agonistic Autoantibodies Against G Protein-Coupled Receptors. Scandinavian Journal of Immunology 70:2, 159-160
CrossRef66
Marlene L. Rose, John D. Smith. (2009) Clinical relevance of complement-fixing antibodies in cardiac transplantation. Human Immunology 70:8, 605-609
CrossRef67
Abdallah S. Geara, Jamil Azzi, Mollie Jurewicz, Reza Abdi. (2009) The renin-angiotensin system: an old, newly discovered player in immunoregulation. Transplantation Reviews 23:3, 151-158
CrossRef68
Yu-Ji Lee, Jung Eun Lee, Sung-Joo Kim, Yoon-Goo Kim, Dae Joong Kim, Ha-Young Oh, Wooseong Huh. (2009) Renal Allograft Outcomes From Spousal and Other Living-Unrelated Donors. Dialysis & Transplantation 38:6, 200-202
CrossRef69
C. Knosalla, K. Yazawa, A. Behdad, N. Bodyak, H. Shang, L. Bühler, S. Houser, B. Gollackner, A. Griesemer, I. Schmitt-Knosalla, H.-J. Schuurman, M. Awwad, D. H. Sachs, D. K. C. Cooper, K. Yamada, A. Usheva, S. C. Robson. (2009) Renal and Cardiac Endothelial Heterogeneity Impact Acute Vascular Rejection in Pig-to-Baboon Xenotransplantation. American Journal of Transplantation 9:5, 1006-1016
CrossRef70
Hiroshi Akazawa, Noritaka Yasuda, Issei Komuro. (2009) Mechanisms and functions of agonist-independent activation in the angiotensin II type 1 receptor. Molecular and Cellular Endocrinology 302:2, 140-147
CrossRef71
Jun Iwanami, Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi. (2009) Inhibition of the renin–angiotensin system and target organ protection. Hypertension Research 32:4, 229-237
CrossRef72
Teresa Kauke, Ingo Kaczmarek, Andrea Dick, Michael Schmoeckel, Marcus-Andre Deutsch, Andres Beiras-Fernandez, Bruno Reichart, Michael Spannagl. (2009) Anti-MICA Antibodies Are Related to Adverse Outcome in Heart Transplant Recipients. The Journal of Heart and Lung Transplantation 28:4, 305-311
CrossRef73
Wendy K. Chung, Liyong Deng, J. Sheila Carroll, Nicole Mallory, Beverly Diamond, Erika Berman Rosenzweig, Robyn J. Barst, Jane H. Morse. (2009) Polymorphism in the Angiotensin II Type 1 Receptor (AGTR1) is Associated With Age at Diagnosis in Pulmonary Arterial Hypertension. The Journal of Heart and Lung Transplantation 28:4, 373-379
CrossRef74
L. Li, P. Wadia, R. Chen, N. Kambham, M. Naesens, T. K. Sigdel, D. B. Miklos, M. M. Sarwal, A. J. Butte. (2009) Identifying compartment-specific non-HLA targets after renal transplantation by integrating transcriptome and "antibodyome" measures. Proceedings of the National Academy of Sciences 106:11, 4148-4153
CrossRef75
Masaki Mogi, Masaru Iwai, Masatsugu Horiuchi. (2009) New insights into the regulation of angiotensin receptors. Current Opinion in Nephrology and Hypertension 18:2, 138-143
CrossRef76
Michael E. Breimer, Lennart Rydberg, Annette M. Jackson, Donna P. Lucas, Andrea A. Zachary, Joseph K. Melancon, Jon Von Visger, Ronald Pelletier, Susan L. Saidman, Winfred W. Williams, Jan Holgersson, Gunnar Tydén, Göran K. Klintmalm, Sonnya Coultrup, Suchitra Sumitran-Holgersson, Per Grufman. (2009) Multicenter Evaluation of a Novel Endothelial Cell Crossmatch Test in Kidney Transplantation. Transplantation 87:4, 549-556
CrossRef77
Duncan J. Campbell. (2009) Angiotensin vaccination: What is the prospect of success?. Current Hypertension Reports 11:1, 63-68
CrossRef78
Z. Kaposztas, H. Podder, S. Mauiyyedi, O. Illoh, R. Kerman, M. Reyes, V. Pollard, B.D. Kahan. (2009) Impact of rituximab therapy for treatment of acute humoral rejection. Clinical Transplantation 23:1, 63-73
CrossRef79
Ralf Dechend, Friedrich C. Luft, Marshall D. Lindheimer. 2009. Agonistic Autoantibody-Mediated Disease. , 287-296.
CrossRef80
Ralf Dechend, Friedrich C. Luft. (2008) Are we getting closer to a Nobel Prize for unraveling preeclampsia?. Current Cardiology Reports 10:6, 440-447
CrossRef81
H. Regele. (2008) Die Rolle von Endothelzellen in der Transplantatabstoßung. Der Pathologe 29:S2, 141-144
CrossRef82
Ajda T. Rowshani, Frederieke J. Bemelman, Neubury M. Lardy, Ineke J.M. Ten Berge. (2008) Humoral immunity in renal transplantation: clinical significance and therapeutic approach. Clinical Transplantation 22:6, 689-699
CrossRef83
Suchitra Sumitran-Holgersson. (2008) Relevance of MICA and other non-HLA antibodies in clinical transplantation. Current Opinion in Immunology 20:5, 607-613
CrossRef84
Duska Dragun. (2008) Humoral Responses Directed Against Non-Human Leukocyte Antigens in Solid-Organ Transplantation. Transplantation 86:8, 1019-1025
CrossRef85
Suchitra Sumitran-Holgersson. (2008) Beyond ABO and human histocompatibility antigen: other histocompatibility antigens with a role in transplantation. Current Opinion in Organ Transplantation 13:4, 425-429
CrossRef86
Samir M Parikh, S Ananth Karumanchi. (2008) Putting pressure on pre-eclampsia. Nature Medicine 14:8, 810-812
CrossRef87
Wolfgang Neuhofer. (2008) Method for diagnosis of a disease involving an anti-endothelin receptor antibody. Expert Opinion on Medical Diagnostics 2:7, 875-878
CrossRef88
Patrizia Amico, Gideon Hönger, Denise Bielmann, Doris Lutz, Daniela Garzoni, Jürg Steiger, Michael J. Mihatsch, Duska Dragun, Stefan Schaub. (2008) Incidence and Prediction of Early Antibody-Mediated Rejection due to Non-Human Leukocyte Antigen-Antibodies. Transplantation 85:11, 1557-1563
CrossRef89
Florian Herse, Anne Cathrine Staff, Lydia Hering, Dominik N. Müller, Friedrich C. Luft, Ralf Dechend. (2008) AT1-receptor autoantibodies and uteroplacental RAS in pregnancy and pre-eclampsia. Journal of Molecular Medicine 86:6, 697-703
CrossRef90
E. Curiel, M.A. Prieto, J. Mora. (2008) Factores relacionados con el desarrollo de preeclampsia. Revisión de la bibliografía. Clínica e Investigación en Ginecología y Obstetricia 35:3, 87-97
CrossRef91
Christophe Mariat. (2008) Early use of renin–angiotensin–aldosterone system inhibitors after renal transplantation. Nature Clinical Practice Nephrology 4:6, 306-307
CrossRef92
H. Hopfer, S. Schaub, M.J. Mihatsch. (2008) Glomeruläre Läsionen bei Transplantatabstoßung. Der Nephrologe 3:3, 222-228
CrossRef93
Josep M. Cruzado, Jorge Rico, Josep M. Grinyó. (2008) The renin angiotensin system blockade in kidney transplantation: pros and cons. Transplant International 21:4, 304-313
CrossRef94
Ziyad Al-Aly, Venkata Reddivari, Abdul Moiz, Geetha Balasubramanian, Cherise M. Cortese, Luis Salinas-Madrigal, Bahar Bastani. (2008) Renal allograft biopsies in the era of C4d staining: the need for change in the Banff classification system. Transplant International 21:3, 268-275
CrossRef95
Lynn D. Cornell, R. Neal Smith, Robert B. Colvin. (2008) Kidney Transplantation: Mechanisms of Rejection and Acceptance. Annual Review of Pathology: Mechanisms of Disease 3:1, 189-220
CrossRef96
Friedrich C. Luft, Ralf Dechend, Duska Dragun, Dominik N. Müller, Gerd Wallukat. (2008) Agonistic antibodies directed at cell surface receptors and cardiovascular disease. Journal of the American Society of Hypertension 2:1, 8-14
CrossRef97
David Jayne. 2008. Plasmapheresis in Renal Diseases. , 125-139.
CrossRef98
Robert B. Colvin, Shamila Mauiyyedi. 2008. Pathology of Kidney Transplantation. , 383-415.
CrossRef99
William J. Burlingham, Robert B. Love, Ewa Jankowska-Gan, Lynn D. Haynes, Qingyong Xu, Joseph L. Bobadilla, Keith C. Meyer, Mary S. Hayney, Ruedi K. Braun, Daniel S. Greenspan, Bagavathi Gopalakrishnan, Junchao Cai, David D. Brand, Shigetoshi Yoshida, Oscar W. Cummings, David S. Wilkes. (2007) IL-17–dependent cellular immunity to collagen type V predisposes to obliterative bronchiolitis in human lung transplants. Journal of Clinical Investigation 117:11, 3498-3506
CrossRef100
G. Bartel, M. Wahrmann, M. Exner, H. Regele, N. Huttary, M. Schillinger, G. F. Körmöczi, W. H. Hörl, G. A. Böhmig. (2007) In Vitro Detection of C4d-Fixing HLA Alloantibodies: Associations With Capillary C4d Deposition in Kidney Allografts. American Journal of Transplantation 0:0, 071105081616007-???
CrossRef101
Daniel J. Salzberg. (2007) Is RAS blockade routinely indicated in hypertensive kidney transplant patients?. Current Hypertension Reports 9:5, 422-429
CrossRef102
Zou, Yizhou, Stastny, Peter, Süsal, Caner, Döhler, Bernd, Opelz, Gerhard, . (2007) Antibodies against MICA Antigens and Kidney-Transplant Rejection. New England Journal of Medicine 357:13, 1293-1300
Full Text103
Brian Susskind. (2007) Methods for histocompatibility testing in the early 21st century. Current Opinion in Organ Transplantation 12:4, 393-401
CrossRef104
Ankit Bharat, T. Mohanakumar. (2007) Allopeptides and the alloimmune response. Cellular Immunology 248:1, 31-43
CrossRef105
J. C. Scornik, G. Guerra, J. D. Schold, T. R. Srinivas, D. Dragun, H.-U. Meier-Kriesche. (2007) Value of Posttransplant Antibody Tests in the Evaluation of Patients with Renal Graft Dysfunction. American Journal of Transplantation 7:7, 1808-1814
CrossRef106
Enver Akalin, Bruno Watschinger. (2007) Antibody-Mediated Rejection. Seminars in Nephrology 27:4, 393-407
CrossRef107
Duska Dragun. (2007) The role of angiotensin II type 1 receptor-activating antibodies in renal allograft vascular rejection. Pediatric Nephrology 22:7, 911-914
CrossRef108
Nicolas Poirier, Frédérick Maillet, Marie-Line Barussaud, Karine Renaudin, Joanna Ashton-Chess, David Minault, Jeremy Hervouet, Jean-Paul Soulillou, Gilles Blancho. (2007) Acute Humoral Rejection of Renal Transplants in Alloimmunized Pigs. Journal of Surgical Research 139:2, 261-268
CrossRef109
Thomas Walther, Holger Stepan. (2007) Agonist autoantibodies against the angiotensin AT1 receptor in renal and hypertensive disorders. Current Hypertension Reports 9:2, 128-132
CrossRef110
Érika B. Rangel, Luiz A. Moura, Marcello F. Franco, Álvaro Pacheco-Silva. (2007) Up-regulation of cyclooxygenase-2 in different grades of acute human renal allograft rejection. Prostaglandins, Leukotrienes and Essential Fatty Acids 76:4, 235-243
CrossRef111
D. Bielmann, G. Hönger, D. Lutz, M. J. Mihatsch, J. Steiger, S. Schaub. (2007) Pretransplant Risk Assessment in Renal Allograft Recipients Using Virtual Crossmatching. American Journal of Transplantation 7:3, 626-632
CrossRef112
Martine J. Smit, Henry F. Vischer, Remko A. Bakker, Aldo Jongejan, Henk Timmerman, Leonardo Pardo, Rob Leurs. (2007) Pharmacogenomic and Structural Analysis of Constitutive G Protein–Coupled Receptor Activity. Annual Review of Pharmacology and Toxicology 47:1, 53-87
CrossRef113
Geng Zhang, He Wang, Fuli Wang, Lei Yu, Xiaojian Yang, Junhua Meng, Weijun Qin, Guojun Wu, Jianhua Li, Angang Yang, Yu Zhou, Rui Zhang. (2007) Gene Polymorphisms of the Renin-Angiotensin-Aldosterone System and Angiotensin II Type 1-Receptor Activating Antibodies in Renal Rejection. The Tohoku Journal of Experimental Medicine 213:3, 203-214
CrossRef114
Georg Heinze, Sean Collins, Michael A. Benedict, Louis L. Nguyen, Reinhard Kramar, Wolfgang C. Winkelmayer, Martin Haas, Alexander Kainz, Rainer Oberbauer. (2006) The Association Between Angiotensin Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use During Postischemic Acute Transplant Failure and Renal Allograft Survival. Transplantation 82:11, 1441-1448
CrossRef115
Noriko Makita, Toshiro Fujita, Taroh Iiri. (2006) Angiotensin receptor 1a. AfCS-Nature Molecule Pages
CrossRef116
Rebecca L. Rich, David G. Myszka. (2006) Survey of the year 2005 commercial optical biosensor literature. Journal of Molecular Recognition 19:6, 478-534
CrossRef117
Mohamad H. Yamani, Daniel J. Cook, E. Rene Rodriguez, Dawn M. Thomas, Sandeep Gupta, Joan Alster, David O. Taylor, Robert Hobbs, James B. Young, Nicholas Smedira, Randall C. Starling. (2006) Increased Expression of Angiotensin II Type 1 Receptor (AGTR1) in Heart Transplant Recipients With Recurrent Rejection. The Journal of Heart and Lung Transplantation 25:11, 1283-1289
CrossRef118
K. A. Pöschel, G. Wolf. (2006) Das Renin-Angiotensin-Aldosteron-System als Zentraler Mediator der Progression der Niereninsuffizienz. Der Nephrologe 1:4, 233-240
CrossRef119
C. Blume, C. E. Kurschat, U. Helmchen, B. Grabensee. (2006) Chronische Transplantatdysfunktion. Der Nephrologe 1:4, 241-254
CrossRef120
J Lutz, K Risch, S Liu, B Antus, C Schmaderer, M Roos, N Ouyang, M Lehmann, U Heemann. (2006) Angiotensin type 1 and type 2 receptor blockade in chronic allograft nephropathy. Kidney International 70:6, 1080-1088
CrossRef121
Suchitra Sumitran-Holgersson, Jan Holgersson. (2006) Clinical importance of non-HLA antibodies in solid organ transplantation. Current Opinion in Organ Transplantation 11:4, 425-432
CrossRef122
Ronald H Kerman, Stanislaw M Stepkowski. (2006) Clinical significance of HLA antigens and non-HLA antigens in solid organ transplantation. Current Opinion in Organ Transplantation 11:4, 418-424
CrossRef123
Marlene L Rose. (2006) Non-HLA antibodies and the role of the autoimmune response in transplant rejection. Current Opinion in Organ Transplantation 11:4, 439-443
CrossRef124
Denis Glotz, Newton Lucchiari, Beatrice Pegaz-Fiornet, Caroline Suberbielle-Boissel. (2006) Endothelial Cells as Targets of Allograft Rejection. Transplantation 82:Supplement 1, S19-S21
CrossRef125
R. B. Mannon. (2006) Therapeutic Targets in the Treatment of Allograft Fibrosis. American Journal of Transplantation 6:5p1, 867-875
CrossRef126
Richard A. Bond, Ad P. IJzerman. (2006) Recent developments in constitutive receptor activity and inverse agonism, and their potential for GPCR drug discovery. Trends in Pharmacological Sciences 27:2, 92-96
CrossRef127
Y. Staudt, C. Trimpert, K. Birkenmeier, T. Krieg, T. Bemmann, D. Beug, S. B. Felix, A. Staudt. (2006) Effects of antibodies obtained from patients with dilated cardiomyopathy on the function of isolated rat hearts. European Journal of Clinical Investigation 36:2, 85-90
CrossRef128
P. Lipták, É. Kemény, Z. Morvay, E. Szederkényi, P. Szenohradszky, F. Marofka, J. Toldi, M. Exner, B. Iványi. (2005) Peritubular Capillary Damage in Acute Humoral Rejection: An Ultrastructural Study on Human Renal Allografts. American Journal of Transplantation 5:12, 2870-2876
CrossRef129
Helmut E Feucht, Michael J Mihatsch. (2005) Diagnostic value of C4d in renal biopsies. Current Opinion in Nephrology and Hypertension 14:6, 592-598
CrossRef130
Robert B. Colvin, R. Neal Smith. (2005) Antibody-mediated organ-allograft rejection. Nature Reviews Immunology 5:10, 807-817
CrossRef131
Charlotte Lawson, Angela L. Holder, Rachel E. Stanford, John Smith, Marlene L. Rose. (2005) Anti???Intercellular Adhesion Molecule-1 Antibodies in Sera of Heart Transplant Recipients: A Role in Endothelial Cell Activation. Transplantation 80:2, 264-271
CrossRef132
(2005) Angiotensin II Type 1–Receptor Activating Antibodies in Renal-Allograft Rejection. New England Journal of Medicine 352:19, 2027-2028
Full Text133
Ruediger W. Lehrich, Paulo N. Rocha, Nancy Reinsmoen, Arthur Greenberg, David W. Butterly, David N. Howell, Stephen R. Smith. (2005) Intravenous Immunoglobulin and Plasmapheresis in Acute Humoral Rejection: Experience in Renal Allograft Transplantation. Human Immunology 66:4, 350-358
CrossRef134
Ingelfinger, Julie R., . (2005) Agonistic Autoantibodies and Rejection of Renal Allografts. New England Journal of Medicine 352:6, 617-619
Full Text
- Letters
